BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 24829271)

  • 1. Validation of DNA methylation biomarkers for diagnosis of acute lymphoblastic leukemia.
    Chatterton Z; Burke D; Emslie KR; Craig JM; Ng J; Ashley DM; Mechinaud F; Saffery R; Wong NC
    Clin Chem; 2014 Jul; 60(7):995-1003. PubMed ID: 24829271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual methylation of tumor suppressor gene promoters, RASSF6 and RASSF10, as novel biomarkers for minimal residual disease detection in adult acute lymphoblastic leukemia.
    Younesian S; Shahkarami S; Ghaffari P; Alizadeh S; Mehrasa R; Ghaffari SH
    Ann Hematol; 2019 Dec; 98(12):2719-2727. PubMed ID: 31486880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. hTERT promoter methylation and telomere length in childhood acute lymphoblastic leukemia: associations with immunophenotype and cytogenetic subgroup.
    Borssén M; Cullman I; Norén-Nyström U; Sundström C; Porwit A; Forestier E; Roos G
    Exp Hematol; 2011 Dec; 39(12):1144-51. PubMed ID: 21914494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation analysis of bone marrow cells at diagnosis of acute lymphoblastic leukemia and at remission.
    Nordlund J; Milani L; Lundmark A; Lönnerholm G; Syvänen AC
    PLoS One; 2012; 7(4):e34513. PubMed ID: 22493696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome.
    Ballerini P; Landman-Parker J; Cayuela JM; Asnafi V; Labopin M; Gandemer V; Perel Y; Michel G; Leblanc T; Schmitt C; Fasola S; Hagemejier A; Sigaux F; Auclerc MF; Douay L; Leverger G; Baruchel A
    Haematologica; 2008 Nov; 93(11):1658-65. PubMed ID: 18835836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
    Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
    Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADAMTSL5 and CDH11: putative epigenetic markers for therapeutic resistance in acute lymphoblastic leukemia.
    Abdullah M; Choo CW; Alias H; Abdul Rahman EJ; Mohd Ibrahim H; Jamal R; Hussin NH
    Hematology; 2017 Aug; 22(7):386-391. PubMed ID: 28292214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
    Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
    N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NKX2-5, SIL/TAL and TLX3/HOX11L2 expression in Egyptian pediatric T-cell acute lymphoblastic leukemia.
    Moussa H; Sidhom I
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):e1-10. PubMed ID: 24571118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
    Gaipa G; Basso G; Biondi A; Campana D
    Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biallelic loss of CDKN2A is associated with poor response to treatment in pediatric acute lymphoblastic leukemia.
    Braun M; Pastorczak A; Fendler W; Madzio J; Tomasik B; Taha J; Bielska M; Sedek L; Szczepanski T; Matysiak M; Derwich K; Lejman M; Kowalczyk J; Kazanowska B; Badowska W; Styczynski J; Irga-Jaworska N; Trelinska J; Zalewska-Szewczyk B; Pierlejewski F; Wlodarska I; Młynarski W;
    Leuk Lymphoma; 2017 May; 58(5):1162-1171. PubMed ID: 27756164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation.
    Seriu T; Yokota S; Nakao M; Misawa S; Takaue Y; Koizumi S; Kawai S; Fujimoto T
    Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring.
    Germano G; del Giudice L; Palatron S; Giarin E; Cazzaniga G; Biondi A; Basso G
    Leukemia; 2003 Aug; 17(8):1573-82. PubMed ID: 12886245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA Methylation Adds Prognostic Value to Minimal Residual Disease Status in Pediatric T-Cell Acute Lymphoblastic Leukemia.
    Borssén M; Haider Z; Landfors M; Norén-Nyström U; Schmiegelow K; Åsberg AE; Kanerva J; Madsen HO; Marquart H; Heyman M; Hultdin M; Roos G; Forestier E; Degerman S
    Pediatr Blood Cancer; 2016 Jul; 63(7):1185-92. PubMed ID: 26928953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
    Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M
    Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology/oncology unit.
    Katsibardi K; Moschovi MA; Braoudaki M; Papadhimitriou SI; Papathanasiou C; Tzortzatou-Stathopoulou F
    Leuk Lymphoma; 2010 May; 51(5):846-52. PubMed ID: 20350276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Real-time quantitative detection of E2A-PBX1 fusion gene in children with acute lymphoblastic leukemia and its clinical application in minimal residual disease monitoring].
    Zhang R; Liao J; Li G; Sun HQ; Shi YJ; Yang JY
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jun; 15(6):440-3. PubMed ID: 23791058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular genetic detection of minimal residual disease (MRD) in children with acute lymphoblastic leukemia].
    Koehler R; Bartram CR
    Klin Padiatr; 2013 May; 225 Suppl 1():S40-4. PubMed ID: 23700054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Genotyping and minimal residual disease study in children with acute myeloid leukemia: preliminary results].
    Balwierz W; Pietrzyk JJ; Wator G; Stozek K; Klekawka T; Kwiecińska K; Dłuzniewska A; Matysiak M; Malinowska I; Sikorska-Fic B; Balcerska A; Maciejka-Kapuścińska L; Sońta-Jakimczyk D; Tomaszewska R; Chybicka A; Krawczuk-Rybak M; Muszyńska-Rosłan K; Młynarski W; Stolarska M; Urasiński T; Kamieńska E; Sobol G; Wieczorek M; Karolczyk G; Wysocki M; Kołtan S; Kowalczyk JR; Wójcik B; Ksiazek T; Szewczyk K
    Przegl Lek; 2010; 67(6):371-4. PubMed ID: 21344764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.